# J.‐P. Lacour

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/j-p-lacour/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,363 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 75 |
| i10-index | 303 |
| Last Known Institution | Centre Hospitalier Universitaire de Nice |
| OpenAlex ID | https://openalex.org/A5058938160 |
| ORCID iD | https://orcid.org/0000-0001-7663-2053 |
| Works | 889 |

## Researcher papers

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)
- [The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from <scp>ASSURE</scp>‐<scp>CSU</scp>](https://scholariq.org/papers/the-burden-of-chronic-spontaneous-urticaria-is-substantial-real-world-evidence/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-multiple-dupilumab-dose-regimens-after-initial-successful/)
- [Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort](https://scholariq.org/papers/effectiveness-and-safety-of-dupilumab-for-the-treatment-of-atopic-dermatitis-in/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [melanin and skin pigmentation](https://scholariq.org/topics/melanin-and-skin-pigmentation/)

## Researcher university

- [Centre Hospitalier Universitaire de Nice](https://scholariq.org/institutions/centre-hospitalier-universitaire-de-nice/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.